Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02493'
s PB Ratio Range Over the Past 10 Years
Min: 1.39 Med: 4.62 Max: 162.22
Current: 125
During the past 9 years, Mabwell (Shanghai) Bioscience Co's highest PB Ratio was 162.22. The lowest was 1.39. And the median was 4.62.
HKSE:02493's PB Ratio is ranked worse than 99.1% of 1223
companies
in the Biotechnology industry
Industry Median: 2.94
vs HKSE:02493: 125.00
During the past 12 months, Mabwell (Shanghai) Bioscience Co's average Book Value Per Share Growth Rate was -92.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -53.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -21.50% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Mabwell (Shanghai) Bioscience Co was 9.60% per year. The lowest was -53.70% per year. And the median was 5.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mabwell (Shanghai) Bioscience Co PB Ratio Related Terms
Mabwell (Shanghai) Bioscience Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02493 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Mabwell (Shanghai) Bioscience Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabwell (Shanghai) Bioscience Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabwell (Shanghai) Bioscience Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mabwell (Shanghai) Bioscience Co's PB Ratio falls into.
Mabwell (Shanghai) Bioscience Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mabwell (Shanghai) Bioscience Co (HKSE:02493) has a PB Ratio of 82.72 as of Aug. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mabwell (Shanghai) Bioscience Co and its competitors. This is 1690% above median its historical median of 4.62. Over the past decade, Mabwell (Shanghai) Bioscience Co's PB Ratio has ranged from 1.39 to 162.22. According to the industry distribution chart, Mabwell (Shanghai) Bioscience Co ranks #1212 out of 1223 companies in the Biotechnology industry, placing it in the top 99.1%.
Is Mabwell (Shanghai) Bioscience Co's PB Ratio too high?
Mabwell (Shanghai) Bioscience Co's current PB Ratio of 82.72 is 1690% above median its 10-year median of 4.62. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 162.22. The Biotechnology industry median PB Ratio is 2.94. Mabwell (Shanghai) Bioscience Co's value of 82.72 is 2713.6% above this industry median. Based on the distribution chart, Mabwell (Shanghai) Bioscience Co ranks #1212 out of 1223 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mabwell (Shanghai) Bioscience Co has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabwell (Shanghai) Bioscience Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabwell (Shanghai) Bioscience Co ranks #1212 out of 1223 companies for PB Ratio. This places Mabwell (Shanghai) Bioscience Co in the lower half of its industry. The industry median PB Ratio is 2.94. Mabwell (Shanghai) Bioscience Co's value of 82.72 is 2713.6% above this benchmark. Historically, Mabwell (Shanghai) Bioscience Co's own PB Ratio has ranged from 1.39 to 162.22 over the past decade. While the company's 10-year median is 4.62 vs. the industry median of 2.94, Mabwell (Shanghai) Bioscience Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mabwell (Shanghai) Bioscience Co's current PB Ratio of 82.72 is 2713.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mabwell (Shanghai) Bioscience Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabwell (Shanghai) Bioscience Co's current PB Ratio is 82.72, which is 1690% above median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabwell (Shanghai) Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Mabwell (Shanghai) Bioscience Co (HKSE:02493) is currently considered Possible Value Trap. The stock's GF Value™ is HK$95.37, compared to a current price of HK$22.50 — trading 76.4% below its estimated fair value. The current PB Ratio is 82.72, which is 1690% above median its 10-year median of 4.62 and 2713.6% above the Biotechnology industry median of 2.94. Mabwell (Shanghai) Bioscience Co's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mabwell (Shanghai) Bioscience Co (HKSE:02493), the current PB Ratio is 82.72 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabwell (Shanghai) Bioscience Co (HKSE:02493) Overvalued in 2026?
Based on GuruFocus' analysis, Mabwell (Shanghai) Bioscience Co stock appears to be undervalued.
The current stock price of HK$22.50 is trading 76.4% below its estimated GF Value™ of HK$95.37.
GuruFocus considers Mabwell (Shanghai) Bioscience Co to be Possible Value Trap.
Key valuation signals for HKSE:02493:
PB Ratio: 82.72 (1690% above median its 10-year median of 4.62)
GF Value™: HK$95.37 vs. price of HK$22.50 (76.4% below fair value)
Industry Position: 2713.6% above the Biotechnology median (#1212 of 1223)
No single metric tells the full story. See the HKSE:02493 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02493 has been successfully added to your 
